Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

Inclusion Criteria: * Postmenopausal woman defined as: 24 consecutive months without a menstrual period and currently not taking any medication known to induce amenorrhea. * Serum estradiol \< 20 pg/mL * Body Mass Index of 35-50 * Stable weight defined as (+/- 5 %) of body weight for at least three months * 40-70 years of age * Fluent in English Exclusion Criteria: * Known hypersensitivity to celecoxib or sulfonamides * Known peptic ulcer disease * Hypertension BP \> 150/90 (on 2 occasions after resting) * Fasting blood glucose \> 165 mg/dL * HIV positive * Screening creatinine \> 2X upper limit of normal * Screening LFT results \> 2x upper limit of normal * Smokers (or stopped \< 3 months ago) * Framingham risk score \> 15 * Evidence of active coronary disease by history and/or EKG * Subjects who consume 25 grams of soy protein/day or more than 45 mg of isoflavones/day, for subjects who consume this amount of soy, they may stop for 14 days prior to admission * Currently taking NSAIDS, aspirin, (if \> once a week, stopped \<30 days ago). * Consuming \> 3 servings of fish or seafood/week * Currently taking fish oil, omega-3 supplements or other herbal supplements that exceed GRAS (Generally Recognized as Safe) levels, (if currently taking fish oil/omega-3 supplements, there must be a 30 day washout period) * Current use of anti-coagulants * Currently taking any weight control medication * Currently taking thioridazine * Currently taking lithium * Currently taking any estrogen/progesterone hormones including vaginal cream, e-string, or vaginal tablets * Currently taking any medication that can alter fat stores as determined by the principal investigator * History of Inflammatory Bowel Disease or other chronic inflammatory disorders * History of any malignancy other than non-melanoma skin cancer in the past 5 years * History of any bleeding disorder * History of cardiovascular disease * Diagnosis of asthma * Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.